Kingdon Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Kingdon Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-77,300	Closed	-$17M	–	105
2021 Q4	$17M	Buy	+77,300	New	+$15M	1.95%	17
2018 Q1	–	Sell	-57,776	Closed	-$8.66M	–	140
2017 Q4	$8.66M	Buy	57,776 +22,164	+62%	+$3.28M	0.56%	58
2017 Q3	$5.41M	Buy	+35,612	New	+$5.36M	0.35%	72

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Kingdon Capital Management's VRTX Position: Q1 2022 in Review

Kingdon Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2022, closing a stake of 77,300 shares — an estimated $17M sold.

Kingdon Capital Management first reported a position in VRTX in Q3 2017 and held it in 3 quarters. The position peaked at $17M in Q4 2021. 1,073 funds tracked by Wall St. Rank hold VRTX as of Q1 2022.

Kingdon Capital Management reported no remaining Vertex Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Kingdon Capital Management sold 77,300 Vertex Pharmaceuticals shares in Q1 2022, an estimated $17M.
Kingdon Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2017 and held it in 3 quarters.
Kingdon Capital Management's Vertex Pharmaceuticals position peaked at $17M in Q4 2021.
1,073 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2022.

Based on Kingdon Capital Management's 13F filing for Q1 2022, filed 16 May 2022.